Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1990 Dec;39(3):239-43.
doi: 10.1016/0090-8258(90)90244-f.

A Randomized Trial of Cyclophosphamide, Doxorubicin, and Cisplatin With or Without Bacillus Calmette-Guerin in Patients With Suboptimal Stage III and IV Ovarian Cancer: A Gynecologic Oncology Group Study

Affiliations
Clinical Trial

A Randomized Trial of Cyclophosphamide, Doxorubicin, and Cisplatin With or Without Bacillus Calmette-Guerin in Patients With Suboptimal Stage III and IV Ovarian Cancer: A Gynecologic Oncology Group Study

W T Creasman et al. Gynecol Oncol. .

Abstract

Four hundred and eleven evaluable patients with suboptimal (greater than 1 cm residual) stage III and IV and recurrent ovarian cancer after surgical exploration and tumor debulking were prospectively randomized to receive cyclophosphamide, doxorubicin, and cisplatin (CAP) with or without bacillus Calmette-Guerin (BCG). Therapy was planned for eight courses with the BCG to be given by the sacrification technique on Days 8 and 15 of each course. The addition of BCG did not improve response rate, progression-free interval (PFI), or survival. In a multivariate analysis prognostic factors significantly favorable for survival include nonmeasurable disease and young age. Those patients having tumor with a mucinous histology had poorer survival and PFI than patients with tumors composed of other cell types.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

Feedback